Cannabinoids for treatment of dystonia in huntington's disease

Journal of Huntington's Disease

Volumn 7, Issue 2, 2018, Pages 167-173

  Saft, Carsten ^a   Von Hein, Sarah Maria ^a   Lucke, Thomas ^b   Thiels, Charlotte ^b   Peball, Marina ^c   Djamshidian, Atbin ^c   Heim, Beatrice ^c   Seppi, Klaus ^c  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cannabinoid; chorea; dronabinol; dystonia; Huntington; Huntington's; nabilone; sativex

Indexed keywords

AMANTADINE; AMISULPRIDE; AMITRIPTYLINE; BACLOFEN; BENSERAZIDE PLUS LEVODOPA; BIPERIDEN; BOTULINUM TOXIN A; CANNABINOID; CLOBAZAM; CLONAZEPAM; DRONABINOL; ESCITALOPRAM; HYDROCHLOROTHIAZIDE; LEVETIRACETAM; LEVODOPA; MEMANTINE; MIRTAZAPINE; NABILONE; NABIXIMOLS; PAROXETINE; PIPAMPERONE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SERTRALINE; TIZANIDINE; TRAZODONE; CANNABIDIOL;

ADOLESCENT; ADULT; AGGRESSION; AGORAPHOBIA; APATHY; ARTICLE; BEHAVIOR DISORDER; BODY WEIGHT GAIN; BRAIN DEPTH STIMULATION; CHOREA; DISEASE DURATION; DRUG TREATMENT FAILURE; DYSTONIA; FAINTNESS; FEMALE; HUMAN; HUNTINGTON CHOREA; HYPERSALIVATION; IRRITABILITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MOTOR PERFORMANCE; NAUSEA AND VOMITING; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANIC; PRIORITY JOURNAL; UNIFIED HUNTINGTON DISEASE RATING SCALE; COMPLICATION; DRUG COMBINATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CANNABIDIOL; CANNABINOIDS; DRONABINOL; DRUG COMBINATIONS; DYSTONIA; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; TREATMENT OUTCOME;

EID: 85047012854     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-170283     Document Type: Article

References (29)

1. Mehrabi NF, Waldvogel HJ, Tippett LJ, Hogg VM, Synek BJ, Faull RL. Symptom heterogeneity in Huntington's disease correlates with neuronal degeneration in the cerebral cortex. Neurobiol Dis. 2016;96:67-74.
2. Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord. 2012;27(1):31-41.
3. Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE. Dosedependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: A case series. BMC Neurol. 2006;6:11.
4. Quigley J. Juvenile Huntington's disease: Diagnostic and treatment considerations for the psychiatrist. Curr Psychiatry Rep. 2017;19(2):9.
5. Hart EP, Marinus J, Burgunder JM, Bentivoglio AR, Craufurd D, Reilmann R, et al. Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease. Mov Disord. 2013;28(8):1142-5.
6. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: An evidence-based review. Curr Pharm Des. 2006;12(21):2701-20.
7. Louis ED, Lee P, Quinn L, Marder K. Dystonia in Huntington's disease: Prevalence and clinical characteristics. Mov Disord. 1999;14(1):95-101.
8. van de Zande NA, Massey TH, McLauchlan D, Pryce Roberts A, Zutt R,Wardle M, et al. Clinical characterization of dystonia in adult patients with Huntington's disease. Eur J Neurol. 2017;24(9):1140-7.
9. Cloud LJ, Jinnah HA. Treatment strategies for dystonia. Expert Opin Pharmacother. 2010;11(1):5-15.
10. Wojtecki L, Groiss SJ, Ferrea S, Elben S, Hartmann CJ, Dunnett SB, et al. A prospective pilot trial for pallidal deep brain stimulation in Huntington's disease. Front Neurol. 2015;6:177.
11. Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015;30(3):313-27.
12. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-63.
13. Armstrong MJ, Miyasaki JM, American Academy of Neurology. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597-603.
14. Muller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington's disease. Mov Disord. 1999;14(6):1038-40.
15. Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci. 2006;18(4):553-4.
16. Lopez-Sendon Moreno JL, Garcia Caldentey J, Trigo Cubillo P, Ruiz Romero C, Garcia Ribas G, Alonso Arias MA, et al.Adouble-blind, randomized, cross-over, placebocontrolled, pilot trial with Sativex in Huntington's disease. J Neurol. 2016;263(7):1390-400.
17. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991;40(3):701-8.
18. Velayudhan L, Van Diepen E, Marudkar M, Hands O, Suribhatla S, Prettyman R, et al. Therapeutic potential of cannabinoids in neurodegenerative disorders: A selective review. Curr Pharm Des. 2014;20(13):2218-30.
19. Pidgeon C, Rickards H. The pathophysiology and pharmacological treatment of Huntington disease. Behav Neurol. 2013;26(4):245-53.
20. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord. 2009;24(15):2254-9.
21. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 2000;97(3):505-19.
22. Glass M, Faull RL, Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience. 1993;56(3):523-7.
23. Consroe P, Kennedy K, Schram K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav. 1991;40(3):517-22.
24. Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J. Cannabinoids: Novel medicines for the treatment of Huntington's disease. Recent Pat CNS Drug Discov. 2012;7(1):41-8.
25. Mansoor K, Zawodniak A, Nadasdy T, Khitan ZJ. Bilateral renal cortical necrosis associated with smoking synthetic cannabinoids. World J Clin Cases. 2017;5(6):234-7.
26. Arjmand S, Vaziri Z, Behzadi M, Abbassian H, Stephens GJ, Shabani M. Cannabinoids and tremor induced by motor-related disorders: Friend or foe? Neurotherapeutics. 2015;12(4):778-87.
27. Chopda GR, Parge V, Thakur GA, Gatley SJ, Makriyannis A, Paronis CA. Tolerance to the diuretic effects of cannabinoids and cross-tolerance to a kappa-opioid agonist in THC-treated mice. J Pharmacol Exp Ther. 2016;358(2):334-41.
28. Paronis CA, Thakur GA, Bajaj S, Nikas SP, Vemuri VK, Makriyannis A, et al. Diuretic effects of cannabinoids. J Pharmacol Exp Ther. 2013;344(1):8-14.
29. Van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411-8.